Department of Pharmacology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53706, United States.
Biochemistry. 2011 Sep 6;50(35):7568-78. doi: 10.1021/bi2004872. Epub 2011 Aug 9.
Sigma receptors are small membrane proteins implicated in a number of pathophysiological conditions, including drug addiction, psychosis, and cancer; thus, small molecule inhibitors of sigma receptors have been proposed as potential pharmacotherapeutics for these diseases. We previously discovered that endogenous monochain N-alkyl sphingolipids, including d-erythro-sphingosine, sphinganine, and N,N-dimethylsphingosine, bind to the sigma-1 receptor at physiologically relevant concentrations [Ramachandran, S., et al. (2009) Eur. J. Pharmacol. 609, 19-26]. Here, we investigated several N-alkylamines of varying chain lengths as sigma receptor ligands. Although the K(I) values for N-alkylamines were found to be in the micromolar range, when N-3-phenylpropyl and N-3-(4-nitrophenyl)propyl derivatives of butylamine (1a and 1b, respectively), heptylamine (2a and 2b, respectively), dodecylamine (3a and 3b, respectively), and octadecylamine (4a and 4b, respectively) were evaluated as sigma receptor ligands, we found that these compounds exhibited nanomolar affinities with both sigma-1 and sigma-2 receptors. A screen of high-affinity ligands 2a, 2b, 3a, and 3b against a variety of other receptors and/or transporters confirmed these four compounds to be highly selective mixed sigma-1 and sigma-2 ligands. Additionally, in HEK-293 cells reconstituted with K(v)1.4 potassium channel and the sigma-1 receptor, these derivatives were able to inhibit the outward current from the channel, consistent with sigma receptor modulation. Finally, cytotoxicity assays showed that 2a, 2b, 3a, and 3b were highly potent against a number of cancer cell lines, demonstrating their potential utility as mixed sigma-1 and sigma-2 receptor anticancer agents.
sigma 受体是一种小的膜蛋白,与许多病理生理状况有关,包括药物成瘾、精神病和癌症;因此,sigma 受体的小分子抑制剂被提议作为这些疾病的潜在治疗药物。我们之前发现,内源性单链 N-烷基神经酰胺,包括 d-erythro-神经鞘氨醇、神经酰胺和 N,N-二甲基神经鞘氨醇,在生理相关浓度下与 sigma-1 受体结合[Ramachandran,S.等人(2009)。Eur. J. Pharmacol. 609, 19-26]。在这里,我们研究了几种不同链长的 N- 烷基胺作为 sigma 受体配体。虽然 N- 烷基胺的 K(i) 值被发现处于微摩尔范围内,但当 N-3- 苯基丙基和 N-3-(4- 硝基苯基)丙基丁基胺(1a 和 1b,分别)、庚基胺(2a 和 2b,分别)、十二烷基胺(3a 和 3b,分别)和十八烷基胺(4a 和 4b,分别)被评估为 sigma 受体配体时,我们发现这些化合物与 sigma-1 和 sigma-2 受体具有纳摩尔亲和力。对高亲和力配体 2a、2b、3a 和 3b 对多种其他受体和/或转运体的筛选证实,这四种化合物是高度选择性的混合 sigma-1 和 sigma-2 配体。此外,在 K(v)1.4 钾通道和 sigma-1 受体重建的 HEK-293 细胞中,这些衍生物能够抑制通道的外向电流,与 sigma 受体调节一致。最后,细胞毒性测定表明,2a、2b、3a 和 3b 对多种癌细胞系具有高活性,表明它们作为混合 sigma-1 和 sigma-2 受体抗癌药物具有潜在用途。